← Back to Screener
Voyager Therapeutics, Inc. Common Stock (VYGR)
Price$3.33
Value ScoreB
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-26.51%
Price vs S&P 500 (4W)-17.77%
VGM Score38.62
Market Capitalization$217.52M
All Metrics
Book Value / Share (Quarterly)$2.88
P/TBV (Annual)5.09x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.43%
Cash Flow / Share (Quarterly)$-2.15
Price vs S&P 500 (YTD)-23.43%
Net Profit Margin (TTM)-319.61%
EPS (TTM)$-1.98
10-Day Avg Trading Volume0.51M
EPS Excl Extra (TTM)$-1.98
Revenue Growth (5Y)-25.08%
EPS (Annual)$-2.04
ROI (Annual)-61.06%
Net Profit Margin (5Y Avg)-125.73%
Cash / Share (Quarterly)$2.35
Revenue Growth QoQ (YoY)-59.94%
ROA (Last FY)-47.46%
Revenue Growth TTM (YoY)-45.50%
EBITD / Share (TTM)$-2.09
ROE (5Y Avg)-36.05%
Operating Margin (TTM)-349.16%
Cash Flow / Share (Annual)$-2.29
P/B Ratio1.25x
P/B Ratio (Quarterly)1.32x
Net Income / Employee (Annual)$-849,100
EV / Revenue (TTM)4.77x
Net Interest Coverage (TTM)-177.00x
ROA (TTM)-43.12%
EV / EBITDA (TTM)12.52x
EPS Incl Extra (Annual)$-2.04
Current Ratio (Annual)7.64x
Quick Ratio (Quarterly)8.20x
3-Month Avg Trading Volume0.65M
52-Week Price Return0.91%
Revenue / Employee (TTM)$258,800
Tangible BV / Share (Quarterly)$4.01
P/S Ratio (Annual)5.39x
Asset Turnover (Annual)0.16x
52-Week High$5.55
Operating Margin (5Y Avg)-140.57%
EPS Excl Extra (Annual)$-2.04
CapEx CAGR (5Y)-26.50%
Tangible BV CAGR (5Y)-15.13%
26-Week Price Return-18.58%
Quick Ratio (Annual)7.60x
13-Week Price Return-15.27%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.42x
Enterprise Value$174.20M
Revenue / Share Growth (5Y)-31.58%
Asset Turnover (TTM)0.13x
Book Value / Share Growth (5Y)-4.25%
Revenue / Employee (Annual)$286,300
Pretax Margin (Annual)-296.17%
Cash / Share (Annual)$3.33
3-Month Return Std Dev72.22%
Net Income / Employee (TTM)$-827,200
ROE (Last FY)-61.06%
EPS Basic Excl Extra (Annual)$-2.04
P/FCF (TTM)3.84x
Receivables Turnover (TTM)19.44x
EV / Free Cash Flow (TTM)0.90x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.98
Receivables Turnover (Annual)19.73x
ROI (TTM)-55.97%
P/S Ratio (TTM)5.96x
Pretax Margin (5Y Avg)-125.38%
Revenue / Share (Annual)$0.69
Tangible BV / Share (Annual)$1.53
Price vs S&P 500 (52W)-23.46%
Year-to-Date Return-15.27%
5-Day Price Return-12.14%
EPS Normalized (Annual)$-2.04
ROA (5Y Avg)-18.43%
Net Profit Margin (Annual)-296.53%
Month-to-Date Return-13.95%
Cash Flow / Share (TTM)$1.34
EBITD / Share (Annual)$-2.18
Operating Margin (Annual)-326.56%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-36.05%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.98
P/TBV (Quarterly)1.71x
P/B Ratio (Annual)1.11x
Pretax Margin (TTM)-319.27%
Book Value / Share (Annual)$3.32
Price vs S&P 500 (13W)-23.52%
Beta1.31x
P/FCF (Annual)2.91x
Revenue / Share (TTM)$0.61
ROE (TTM)-55.97%
52-Week Low$2.83
vGradeB
gGradeF
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.47est. -0.56
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.39
4.39
4.39
4.39
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VYGRVoyager Therapeutics, Inc. Common Stock | B | F | D | $3.33 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Voyager Therapeutics is a gene therapy company developing AAV-based treatments for severe neurological diseases. The company's proprietary TRACER platform enables the engineering, optimization, and delivery of therapies designed to achieve durable efficacy following single-dose administration. Its pipeline includes programs targeting tau-related neurodegeneration, SOD1 overexpression disorders, and Friedreich's ataxia.